CSF3 and Hodgkins lymphoma: In a Phase 2 pilot study, Burixafor combined with G-CSF successfully mobilized HSCs into the peripherial blood in patients with non-Hodking lymphoma (NHL), Hodgkin lymphoma (HL) and MM [170].